387
edits
Changes
no edit summary
{{Drugcombi
| base = quetiapine
| add = valproic acid
| info =
* Quetiapine is principally metabolized by CYP3A4 to active and inactive metabolites.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects. Dose adaptation will be recommended for this combination. <ref> {{Pubmed|18579216|Vieta E at al, Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008 Aug;109(3):251-63. Epub 2008 Jun 24}}</ref>
| start =
* Start valproic acid according to the general dosing advice.
| cave =
* During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. <ref name="drugscom">
{{Drugscominteract|quetiapine-with-valproic-acid-1979-1274-2286-0|quetiapine|valproic acid}}</ref>
}}
